Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Clinical trial NCT07155226 · RECRUITING

Trial details

NCT number: NCT07155226
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukaemia Acute Myeloid Leukaemia Higher-risk Myelodysplastic Syndromes

Start date: 2026-01-09
Primary completion: 2029-02-15
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.